Tilray Brands (TLRY) has never been a one-note company. It straddles cannabis, craft beverages, hemp-based wellness, and even entertainment — building a portfolio that spans more than 40 brands across 20 countries. Yet, for all its global reach, TLRY stock often behaves like a risky roll of the dice.
Last week, TLRY stock ripped more than 70% higher before paring back some of the gains by Friday, Aug. 15. The spark came from President Donald Trump floating the idea of reclassifying marijuana to Schedule III. That’s a seismic shift that could unlock broader medical use, loosen restrictions, and finally bring cannabis companies out of regulatory purgatory. Meanwhile, Tilray deepened its European footprint, collaborating with Italian pharma player Molteni, underscoring its ambition beyond North America.
